HRP20200032T1 - Antibody drug conjugates - Google Patents

Antibody drug conjugates Download PDF

Info

Publication number
HRP20200032T1
HRP20200032T1 HRP20200032TT HRP20200032T HRP20200032T1 HR P20200032 T1 HRP20200032 T1 HR P20200032T1 HR P20200032T T HRP20200032T T HR P20200032TT HR P20200032 T HRP20200032 T HR P20200032T HR P20200032 T1 HRP20200032 T1 HR P20200032T1
Authority
HR
Croatia
Prior art keywords
group
alkylene
substituents
substituted
optionally
Prior art date
Application number
HRP20200032TT
Other languages
Croatian (hr)
Inventor
Cármen CUEVAS MARCHANTE
Juan Manuel DOMÍNGUEZ CORREA
Andrés FRANCESCH SOLLOSO
María GARRANZO GARCÍA-IBARROLA
María José MUNOZ ALONSO
Francisco SÁNCHEZ MADRID
Juan Manuel ZAPATA HERNÁNDEZ
Alicia García Arroyo
Maria Ángeles URSA PECHARROMÁN
Original Assignee
Pharma Mar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar S.A. filed Critical Pharma Mar S.A.
Publication of HRP20200032T1 publication Critical patent/HRP20200032T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (31)

1. Konjugat lijeka koji sadrži segment lijeka kovalentno vezan za ostatak konjugata lijeka, spoj koji ima formulu [D-(X)b-(AA)w-(L)-]n-Ab, gdje D je segment lijeka odabran od formula (Ia) i (Ib), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog,1. A drug conjugate containing a drug segment covalently bound to the rest of the drug conjugate, a compound having the formula [D-(X)b-(AA)w-(L)-]n-Ab, where D is a drug segment selected from the formula ( Ia) and (Ib), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, gdje valovite linije od (Ia) i (Ib) označavaju točku kovalentnog vezivanja za (X)b ako postoji, ili (AA)w ako postoji, ili vezujuću grupu L; A je odabran od gdje valovite linije segmenta A označavaju točku kovalentnog vezivanja za ostatak segmenta lijeka; svaki od R1, R2 i R3 je nezavisno odabran od vodika, ORa, OCORa, OCOORa, NRaRb, NRaCORb, NRaC(=NRa)NRaRb, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila, gdje su opcionalni supstituenti jedan ili više supstituenata Rx; R3' je odabran od vodika, CORa, COORa, CONRaRb, S(O)Ra, SO2Ra, P(O)(Ra)Rb, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila, gdje su opcionalni supstituenti jedan ili više supstituenata Rx; svaki od R4, R5, R6, R7, R8, R9, R10 i R12 je nezavisno odabran iz grupe koja se sastoji od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila, gdje su opcionalni supstituenti jedan ili više supstituenata Rx; R11 je odabran iz grupe koja se sastoji od vodika, CORa, COORa, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila, ili R11 i R12 zajedno sa odgovarajućim atomom N i atomom C za koji su vezani mogu da formiraju 5- do 14-očlanu supstituiranu ili nesupstituiranu nezasićenu ili zasićenu heterocikličnu grupu koja ima jedan ili više prstenova i koja po izboru sadrži jedan ili više dodatnih heteroatoma odabranih od atoma kisika, dušika i sumpora u navedenom(im) prstenu(ovima) dodatno atomu dušika iz NR11, gdje su opcionalni supstituenti jedan ili više supstituenata Rx; R13 je odabran iz grupe koja se sastoji od vodika, CORa, COORa, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila, i supstituiranog ili nesupstituiranog C4-C12 alkeninila, gdje su opcionalni supstituenti jedan ili više supstituenata Rx; svaki od R15, R16, R17, R17', R18', R24, R24', R25 i R26 je nezavisno odabran iz grupe koja se sastoji od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila, gdje su opcionalni supstituenti jedan ili više supstituenata Rx; R18 je odabran iz grupe koja se sastoji od vodika, C1-C12 alkil grupa koje mogu po izboru biti supstituirane sa najmanje jednom grupom Rx, aril grupa koje imaju od 6 do 18 atoma ugljika u jednom ili više aromatičnih prstenova, pri čemu navedene aril grupe su po izboru supstituirane sa jednim ili više supstituenata Rx, i 5- do 14-očlanih supstituiranih ili nesupstituiranih nezasićenih ili zasićenih heterocikličnih grupa koje imaju jedan ili više prstenova, gdje su opcionalni supstituenti jedan ili više supstituenata Rx; R27 je odabran od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila i halogena; svaki od Ra i Rb je nezavisno odabran iz grupe koja se sastoji od vodika, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila, supstituiranih ili nesupstituiranih aril grupa koje imaju od 6 do 18 atoma ugljika u jednom ili više prstenova, i 5- do 14-očlanih supstituiranih ili nesupstituiranih nezasićenih ili zasićenih heterocikličnih grupa koje imaju jedan ili više prstenova, gdje su opcionalni supstituenti jedan ili više supstituenata Rx; supstituenti Rx su odabrani iz grupe koja se sastoji od C1-C12 alkil grupa koje mogu biti po izboru supstituirane sa najmanje jednom grupom Ry, C2-C12 alkenil grupa koje mogu biti po izboru supstituirane sa najmanje jednom grupom Ry, C2-C12 alkinil grupa koje mogu biti po izboru supstituirane sa najmanje jednom grupom Ry, halogenih atoma, okso grupa, tio grupa, cijano grupa, nitro grupa, ORy, OCORy, OCOORy, CORy, COORy, OCONRyRz, CONRyRz, S(O)Ry, SO2Ry, P(O)(Ry)ORz, NRyRz, NRyCORz, NRyC(=O)NRyRz, NRyC(=NRy)NRyRz, aril grupa koje imaju od 6 do 18 atoma ugljika u jednom ili više prstenova koje mogu po izboru biti supstituirane sa jednim ili više supstituenata koji mogu biti isti ili različiti odabrani iz grupe koja se sastoji od Ry, ORy, OCORy, OCOORy, NRyRz, NRyCORz i NRyC(=NRy)NRyRz, aralkil grupa koje sadrže alkil grupu koja ima od 1 do 12 atoma ugljika supstituiranu sa opcionalno supstituiranom aril grupom kao što je definirano iznad, aralkiloksi grupa koje sadrže alkoksi grupu koja ima od 1 do 12 atoma ugljika supstituiranu sa opcionalno supstituiranom aril grupom kao što je definirano iznad, i 5- do 14-očlane zasićene ili nezasićene heterociklične grupe koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu navedena heterociklična grupa je po izboru supstituirana sa jednim ili više supstituenata Ry, i gdje postoji više od jednog opcionalnog supstituenta na bilo kojoj danoj grupi opcionalni supstituenti Ry mogu biti isti ili različiti; svaki Ry i Rz je nezavisno odabran iz grupe koja se sastoji od vodika, C1-C12 alkil grupa, C1-C12 alkil grupa koje su supstituirane sa najmanje jednim atomom halogena, aralkil grupa koje sadrže C1-C12 alkil grupu koja je supstituirana sa aril grupom koja ima od 6 do 18 atoma ugljika u jednom ili više prstenova i heterocikloalkil grupa koje sadrže C1-C12 alkil grupu koja je supstituirana sa 5- do 14-očlanom nezasićenom ili zasićenom heterocikličnom grupom koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima); i svaka isprekidana linija predstavlja opcionalno dodatnu vezu, ali kada trostruka veza postoji između C atoma za koji je R25 vezan i C atoma za koji su R26 i R27 vezani, tada su R25 i bilo R26 bilo R27 odsutni; L je vezujuća grupa odabrana iz grupe koja se sastoji od:where the wavy lines of (Ia) and (Ib) indicate the point of covalent attachment to (X)b if present, or (AA)w if present, or the linking group L; A is selected from where the wavy lines of segment A indicate the point of covalent attachment to the rest of the segment medicine; each of R1, R2 and R3 is independently selected from hydrogen, ORa, OCORa, OCOORa, NRaRb, NRaCORb, NRaC(=NRa)NRaRb, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl and substituted or unsubstituted C2 -C12 alkynyl, where the optional substituents are one or more substituents Rx; R3' is selected from hydrogen, CORa, COORa, CONRaRb, S(O)Ra, SO2Ra, P(O)(Ra)Rb, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2 -C12 alkynyl, where the optional substituents are one or more substituents Rx; each of R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 12 is independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 12 alkyl, substituted or unsubstituted C 2 -C 12 alkenyl, and substituted or unsubstituted C 2 -C 12 alkynyl, wherein the optional substituents are one or more substituents Rx; R11 is selected from the group consisting of hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl and substituted or unsubstituted C2-C12 alkynyl, or R11 and R12 together with the corresponding N atom and C to which they are attached can form a 5- to 14-membered substituted or unsubstituted unsaturated or saturated heterocyclic group having one or more rings and optionally containing one or more additional heteroatoms selected from oxygen, nitrogen and sulfur atoms in the specified ) to the ring(s) in addition to the nitrogen atom from NR11, where the optional substituents are one or more substituents Rx; R 13 is selected from the group consisting of hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenyl, where optional substituents one or more substituents Rx; each of R15, R16, R17, R17', R18', R24, R24', R25 and R26 is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl and substituted or unsubstituted C2-C12 alkynyl, where optional substituents are one or more substituents Rx; R18 is selected from the group consisting of hydrogen, C1-C12 alkyl groups which can optionally be substituted with at least one Rx group, aryl groups having from 6 to 18 carbon atoms in one or more aromatic rings, wherein said aryl groups are optionally substituted with one or more substituents Rx, and 5- to 14-membered substituted or unsubstituted unsaturated or saturated heterocyclic groups having one or more rings, where the optional substituents are one or more substituents Rx; R 27 is selected from hydrogen, substituted or unsubstituted C 1 -C 12 alkyl and halogen; each of Ra and Rb is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl groups having from 6 to 18 carbon atoms in one or more rings, and 5- to 14-membered substituted or unsubstituted unsaturated or saturated heterocyclic groups having one or more rings, where the optional substituents are one or more substituents Rx; substituents Rx are selected from the group consisting of C1-C12 alkyl groups which can be optionally substituted with at least one Ry group, C2-C12 alkenyl groups which can be optionally substituted with at least one Ry group, C2-C12 alkynyl groups which may optionally be substituted with at least one Ry group, halogen atoms, oxo group, thio group, cyano group, nitro group, ORy, OCORy, OCOORy, CORy, COORy, OCONRyRz, CONRyRz, S(O)Ry, SO2Ry, P( O)(Ry)ORz, NRyRz, NRyCORz, NRyC(=O)NRyRz, NRyC(=NRy)NRyRz, aryl groups having from 6 to 18 carbon atoms in one or more rings which may optionally be substituted with one or more substituents which may be the same or different selected from the group consisting of Ry, ORy, OCORy, OCOORy, NRyRz, NRyCORz and NRyC(=NRy)NRyRz, aralkyl groups containing an alkyl group having from 1 to 12 carbon atoms optionally substituted with by a substituted aryl group as defined above, aralkyloxy groups containing an alkoxy group which has from 1 to 12 carbon atoms substituted with an optionally substituted aryl group as defined above, and a 5- to 14-membered saturated or unsaturated heterocyclic group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said heterocyclic group is optionally substituted with one or more substituents Ry, and where there is more than one optional substituent on any given group, the optional substituents Ry may be the same or different; each Ry and Rz is independently selected from the group consisting of hydrogen, a C1-C12 alkyl group, a C1-C12 alkyl group substituted with at least one halogen atom, an aralkyl group containing a C1-C12 alkyl group substituted with an aryl group having from 6 to 18 carbon atoms in one or more rings and heterocycloalkyl groups containing a C1-C12 alkyl group that is substituted with a 5- to 14-membered unsaturated or saturated heterocyclic group having one or more rings and containing at least one atom oxygen, nitrogen or sulfur in said ring(s); and each dashed line represents an optional additional bond, but when a triple bond exists between the C atom to which R 25 is attached and the C atom to which R 26 and R 27 are attached, then R 25 and either R 26 or R 27 are absent; L is a linking group selected from the group consisting of: gdje valovite linije označavaju točku kovalentnih vezivanja za Ab (valovita linija na desno) i (AA)w ako postoji, ili (X)b ako postoji, ili segment lijeka (valovita linija na lijevo); R19 je odabran od -C1-C12 alkilen-, -C3-C8 karbociklo, -O-(C1-C12 alkilen), -C6-C18 arilen u jednom ili više prstenova koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx, -C1-C12 alkilen-C6-C18 arilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, -C6-C18 arilen-C1-C12 alkilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, -C1-C12 alkilen-(C3-C8 karbociklo)-, -(C3-C8 karbociklo)-C1-C12 alkilen-, -C5-C14 heterociklo- gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -C1-C12 alkilen-(C5-C14 heterociklo)- gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -(C5-C14 heterociklo)-C1-C12 alkilen-gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -(OCH2CH2)r- i -CH2-(OCH2CH2)r-, gdje svaki od iznad navedenih alkilen supstituenata bilo zaseban ili vezan za drugi segment ugljikovog lanca može po izboru biti supstituiran sa jednim ili više supstituenata Rx; M je odabran iz grupe koja se sastoji od -C1-C6 alkilen-, -C1-C6 alkilen-(C3-C8 karbociklo)-, -(CH2CH2O)s-, -C1-C6 alkilen-(C3-C8 karbociklo)-CON(H ili C1-C6alkil-C1-C6 alkilen-, fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx, fenilen-C1-C6 alkilen- gdje fenilen segment može po izboru biti supstituiran sa jednim ili više supstituenata Rx i -C1-C6 alkilen-CON(H ili C1-C6alkil)C1-C6 alkilen-; Q je odabran iz grupe koja se sastoji od -N(H ili C1-C6 alkil)fenilen- i -N(H ili C1-C6alkil)-(CH2)s; r je cijeli broj u opsegu od 1 do 10; i s je cijeli broj u opsegu od 1 do 10; (AA)w je formule (II): gdje valovite linije označavaju točku kovalentnih vezivanja za (X)b ako postoji, ili segment lijeka (valovita linija na lijevo) i za veznik (valovita linija na desno); R21 je, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od vodika, metila, izopropila, izobutila, sek-butila, benzila, p-hidroksibenzila, -CH2OH, -CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, -CH2CH2COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, -(CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -(CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-piridilmetil-, 3-piridilmetil-, 4-piridilmetil-, fenil, cikloheksil,where wavy lines indicate the point of covalent attachment to Ab (wavy line to the right) and (AA)w if present, or (X)b if present, or the drug segment (wavy line to the left); R19 is selected from -C1-C12 alkylene-, -C3-C8 carbocyclo, -O-(C1-C12 alkylene), -C6-C18 arylene in one or more rings which can optionally be substituted with one or more substituents Rx, -C1-C12 alkylene-C6-C18 arylene- where the arylene group is in one or more rings which can optionally be substituted with one or more substituents Rx, -C6-C18 arylene-C1-C12 alkylene- where the arylene group is in one or several rings which can optionally be substituted with one or more substituents Rx, -C1-C12 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C12 alkylene-, -C5-C14 heterocyclo- where said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -C1-C12 alkylene-(C5-C14 heterocyclo)- where the specified heterocyclo group can be a saturated or unsaturated group co i has one or more rings and which contains at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -(C5-C14 heterocyclo)- C1-C12 alkylene-where said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -(OCH2CH2)r- and -CH2-(OCH2CH2)r-, where each of the above-mentioned alkylene substituents either separately or attached to another segment of the carbon chain can optionally be substituted with one or more substituents Rx ; M is selected from the group consisting of -C1-C6 alkylene-, -C1-C6 alkylene-(C3-C8 carbocyclo)-, -(CH2CH2O)s-, -C1-C6 alkylene-(C3-C8 carbocyclo)- CON(H or C1-C6alkyl-C1-C6 alkylene-, phenylene which can be optionally substituted with one or more substituents Rx, phenylene-C1-C6 alkylene- where the phenylene segment can be optionally substituted with one or more substituents Rx and -C1-C6 alkylene-CON(H or C1-C6alkyl)C1-C6 alkylene-; Q is selected from the group consisting of -N(H or C1-C6 alkyl)phenylene- and -N(H or C1-C6 alkyl)-(CH2)s; r is an integer in the range from 1 to 10; and s is an integer in the range from 1 to 10; (AA)w is of formula (II): where the wavy lines indicate the point of covalent attachment to (X)b if present, or the drug segment (wavy line to the left) and to the linker (wavy line to the right); R21 is, at each occurrence, selected from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH , -CH2CH2CONH2, -CH2CH2COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, -(CH2)4NHC(=NH)NH2, -(CH2 )4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -(CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-pyridylmethyl-, 4-pyridylmethyl-, phenyl , cyclohexyl, i w je cijeli broj u opsegu od 0 do 12; X je grupa za produžavanje odabrana iz grupe koja se sastoji od: -CONH-(C1-C6 alkilen)NH-; -COO-CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx)-NH-; -CONH-(C1-C6 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx)-NH-; -CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx)-NH-; -COCH2N H-COCH2-N H-; -COCH2NH-; -CONH-(C1-C6 alkilen)S-; -CONH-(C1-C6 alkilen)NHCO(C1-C6 alkilen)S-; -(C1-C6 alkilen)NHCO(C1-C6 alkilen)S-; -(C1-C6 alkilen)S-; -(C1-C6 alkilen)NH-; i -(C1-C6 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx)-NH-. b je cijeli broj od 0 ili 1; Ab je segment koji sadrži najmanje jedno antigen vezujuće mjesto; i n je odnos grupe [D-(X)b-(AA)w-(L)-] prema segmentu koji sadrži najmanje jedno antigen vezujuće mjesto i u opsegu je od 1 do 20.and w is an integer in the range from 0 to 12; X is an extension group selected from the group consisting of: -CONH-(C1-C6 alkylene)NH-; -COO-CH2-(phenylene which can optionally be substituted with one or more substituents Rx)-NH-; -CONH-(C1-C6 alkylene)NH-COO-CH2-(phenylene which can optionally be substituted with one or more substituents Rx)-NH-; -CH2-(phenylene which can optionally be substituted with one or more substituents Rx)-NH-; -COCH2N H-COCH2-N H-; -COCH2NH-; -CONH-(C1-C6 alkylene)S-; -CONH-(C1-C6 alkylene)NHCO(C1-C6 alkylene)S-; -(C1-C6 alkylene)NHCO(C1-C6 alkylene)S-; -(C1-C6 alkylene)S-; -(C1-C6 alkylene)NH-; and -(C1-C6 alkylene)NH-COO-CH2-(phenylene which can optionally be substituted with one or more substituents Rx)-NH-. b is an integer of 0 or 1; Ab is a segment containing at least one antigen binding site; and n is the ratio of the group [D-(X)b-(AA)w-(L)-] to the segment containing at least one antigen binding site and is in the range of 1 to 20. 2. Konjugat lijeka prema patentnom zahtjevu 1, gdje: L je vezujuća grupa odabrana iz grupe koja se sastoji od: i gdje: valovite linije označavaju točku kovalentnih vezivanja za Ab (valovita linija na desno) i (AA)w ako postoji, ili (X)b ako postoji, ili segment lijeka (valovita linija na lijevo); R19 je odabran od -C1-C12 alkilen-, -O-(C1-C12 alkilen), -C6-C12 arilen u jednom ili više prstenova koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx, -C1-C12 alkilen-C6-C12 arilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, -C6-C12 arilen-C1-C12 alkilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, -C5-C12 heterociklo- gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -C1-C12 alkilen-(C5-C12 heterociklo)- gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -(C5-C12 heterociklo)-C1-C12 alkilen-gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -(OCH2CH2)r- i -CH2-(OCH2CH2)r-, gdje svaki od iznad navedenih alkilen supstituenata bilo zaseban ili vezan za segment ugljikovog lanca može po izboru biti supstituiran sa jednim ili više supstituenata Rx; M je odabran iz grupe koja se sastoji od -C1-C6 alkilen-, -C1-C6 alkilen-(C3-C8 karbociklo)- i fenilena koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx; r je cijeli broj u opsegu od 1-6; (AA)w je formule (II): gdje valovite linije označavaju točku kovalentnih vezivanja za (X)b ako postoji, ili segment lijeka (valovita linija na lijevo) i za veznik (valovita linija na desno); R21 je, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od vodika, metila, izopropila, izobutila, sek-butila, benzila, p-hidroksibenzila, -CH2OH, -CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH, -CH2CH2CONH2, -CH2CH2COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, -(CH2)4NHC(=NH)NH2, -(CH2)4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -(CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-piridilmetil-, 3- piridilmetil-, 4-piridilmetil-, fenila, cikloheksila,2. Drug conjugate according to claim 1, where: L is a linking group selected from the group consisting of: and where: wavy lines indicate the point of covalent attachment to Ab (wavy line to the right) and (AA)w if present, or (X)b if present, or the drug segment (wavy line to the left); R19 is selected from -C1-C12 alkylene-, -O-(C1-C12 alkylene), -C6-C12 arylene in one or more rings which can optionally be substituted with one or more substituents Rx, -C1-C12 alkylene- C6-C12 arylene- where the arylene group is in one or more rings which can optionally be substituted with one or more substituents Rx, -C6-C12 arylene-C1-C12 alkylene- where the arylene group is in one or more rings which can to be optionally substituted with one or more substituents Rx, -C5-C12 heterocyclo- where the said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in the said ring(s) these), wherein said group is optionally substituted with one or more substituents Rx, -C1-C12 alkylene-(C5-C12 heterocyclo)- where said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -(C5-C12 heterocyclo)-C1-C12 alkylene-where said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -(OCH2CH2)r- and -CH2-( OCH2CH2)r-, where each of the above-mentioned alkylene substituents, whether separate or attached to a carbon chain segment, can optionally be substituted with one or more substituents Rx; M is selected from the group consisting of -C1-C6 alkylene-, -C1-C6 alkylene-(C3-C8 carbocyclo)- and phenylene which may optionally be substituted with one or more substituents Rx; r is an integer in the range of 1-6; (AA)w is of formula (II): where the wavy lines indicate the point of covalent attachment to (X)b if present, or a segment of the drug (wavy line to the left) and for the conjunction (wavy line to the right); R21 is, at each occurrence, selected from the group consisting of hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH2OH, -CH(OH)CH3, -CH2CH2SCH3, -CH2CONH2, -CH2COOH , -CH2CH2CONH2, -CH2CH2COOH, -(CH2)3NHC(=NH)NH2, -(CH2)3NH2, -(CH2)3NHCOCH3, -(CH2)3NHCHO, -(CH2)4NHC(=NH)NH2, -(CH2 )4NH2, -(CH2)4NHCOCH3, -(CH2)4NHCHO, -(CH2)3NHCONH2, -(CH2)4NHCONH2, -CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3- pyridylmethyl-, 4-pyridylmethyl-, phenyl , cyclohexyl, w je cijeli broj u opsegu od 0 do 12; gdje X je grupa za produžavanje odabrana od -CONH-(C1-C6 alkilen)NH-, -COO-CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx)-NH-, -CONH-(C1-C6 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx)-NH-, -CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx)-NH-, -COCH2NH-COCH2-NH-, -COCH2-NH-, -CONH-(C1-C6 alkilen)S-, -CONH-(C1-C6 alkilen)NHCO(C1-C6 alkilen)S-, -(C1-C6 alkilen)NHCO(C1-C6 alkilen)S-, -(C1-C6 alkilen)S-, -(C1-C6 alkilen)NH- i -(C1-C6 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx)-NH-; D je segment lijeka formule (Ia) ili formule (lb), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog gdje: R1 je odabran od vodika, ORa i OCORa, gdje Ra je odabran od vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; R2 i R3 su svaki nezavisno odabrani od vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; R3' je odabran od vodika, CORa, i supstituiranog ili nesupstituiranog C1-C6 alkila, gdje Ra je supstituiran ili nesupstituiran C1-C6 alkil, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; Svaki od R4, R5, R6, R7, R8, R9, R10 i R12 je nezavisno odabran od vodika i supstituiranog i nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; R11 i R13 su nezavisno odabrani od vodika i supstituiranog i nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; svaki od R15, R16, R17, R17', R18', R24, R24', R25 i R26 je nezavisno odabran iz grupe koja se sastoji od: vodika i supstituiranih ili nesupstituiranih C1-C6 alkil grupa gdje opcionalni supstituenti su odabrani iz grupe koja se sastoji od alkoksi grupa koje imaju od 1 do 6 atoma ugljika, hidroksil grupa, okso grupa, atoma halogena, OCORy, OCOORy, CORy, COORy, OCONRyRz, CONRyRz, NRyRz i NRyCORz, gdje svaki od Ry i Rz je odabran od atoma vodika i alkil grupa koje imaju od 1 do 6 atoma ugljika; R18 je odabran od vodika, C1-C6 alkil grupe koja može po izboru biti supstituirana sa najmanje jednom grupom Rx, aril grupe koja ima od 6 do 12 atoma ugljika u jednom ili više aromatičnih prstenova, pri čemu su navedene aril grupe po izboru supstituirane sa jednim ili više supstituenata Rx i 5- do 10-očlane nezasićene ili zasićene heterociklične grupe koja ima jedan ili više prstenova, pri čemu je navedena heterociklična grupa po izboru supstituirana sa jednim ili više supstituenata Rx, gdje supstituenti Rx su odabrani iz grupe koja se sastoji od alkoksi grupa koje imaju od 1 do 6 atoma ugljika, hidroksil grupa, atoma halogena, alkilamino grupa koje imaju od 1 do 6 atoma ugljika i dialkilamino grupa koje imaju od 1 do 6 atoma ugljika; R27 je odabran od vodika, halogena i supstituiranog i nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; svaka isprekidana linija predstavlja opcionu dodatnu vezu, ali kada trostruka veza postoji između C atoma za koji je R25 vezan i C atoma za koji su R26 i R27 vezani, tada R25 i bilo R26 bilo R27 su odsutni; segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je antitijelo ili antigen-vezujući fragment istog i odabrano je iz grupe koja se sastoji od humanog antitijela, antigen-vezujućeg fragmenta humanog antitijela, humaniziranog antitijela, antigen-vezujućeg fragmenta humaniziranog antitijela, himernog antitijela, antigen-vezujućeg fragmenta himernog antitijela, glikoziliranog antitijela i glikoziliranog antigen vezujućeg fragmenta; i n je odnos grupe [D-(X)b-(AA)w-(L)-] prema segmentu Ab koji sadrži najmanje jedno antigen vezujuće mjesto i u opsegu je od 1 do 12.w is an integer in the range from 0 to 12; where X is an extending group selected from -CONH-(C1-C6 alkylene)NH-, -COO-CH2-(phenylene which may optionally be substituted with one or more substituents Rx)-NH-, -CONH-(C1- C6 alkylene)NH-COO-CH2-(phenylene which can be optionally substituted with one or more substituents Rx)-NH-, -CH2-(phenylene which can be optionally substituted with one or more substituents Rx)-NH-, -COCH2NH-COCH2-NH-, -COCH2-NH-, -CONH-(C1-C6 alkylene)S-, -CONH-(C1-C6 alkylene)NHCO(C1-C6 alkylene)S-, -(C1-C6 alkylene)NHCO(C1-C6 alkylene)S-, -(C1-C6 alkylene)S-, -(C1-C6 alkylene)NH- and -(C1-C6 alkylene)NH-COO-CH2-(phenylene which can optionally substituted with one or more substituents Rx)-NH-; D is a drug segment of formula (Ia) or formula (lb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof where: R1 is selected from hydrogen, ORa and OCORa, where Ra is selected from hydrogen and substituted or unsubstituted C1-C6 alkyl, where optional substituents are one or more substituents Rx; R2 and R3 are each independently selected from hydrogen and substituted or unsubstituted C1-C6 alkyl, wherein optional substituents are one or more substituents Rx; R3' is selected from hydrogen, CORa, and substituted or unsubstituted C1-C6 alkyl, wherein Ra is substituted or unsubstituted C1-C6 alkyl, wherein optional substituents are one or more substituents Rx; Each of R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 12 is independently selected from hydrogen and substituted and unsubstituted C 1 -C 6 alkyl, wherein optional substituents are one or more substituents R x ; R11 and R13 are independently selected from hydrogen and substituted and unsubstituted C1-C6 alkyl, where optional substituents are one or more substituents Rx; each of R15, R16, R17, R17', R18', R24, R24', R25 and R26 is independently selected from the group consisting of: hydrogen and substituted or unsubstituted C1-C6 alkyl groups where the optional substituents are selected from the group consisting of alkoxy groups having from 1 to 6 carbon atoms, hydroxyl groups, oxo groups, halogen atoms, OCORy, OCOORy, CORy, COORy, OCONRyRz , CONRyRz, NRyRz and NRyCORz, wherein each of Ry and Rz is selected from hydrogen atoms and alkyl groups having from 1 to 6 carbon atoms; R18 is selected from hydrogen, a C1-C6 alkyl group which can optionally be substituted with at least one Rx group, an aryl group having from 6 to 12 carbon atoms in one or more aromatic rings, wherein said aryl groups are optionally substituted with by one or more substituents Rx and a 5- to 10-membered unsaturated or saturated heterocyclic group having one or more rings, wherein said heterocyclic group is optionally substituted with one or more substituents Rx, where the substituents Rx are selected from the group consisting of from alkoxy groups having from 1 to 6 carbon atoms, hydroxyl groups, halogen atoms, alkylamino groups having from 1 to 6 carbon atoms and dialkylamino groups having from 1 to 6 carbon atoms; R27 is selected from hydrogen, halogen, and substituted and unsubstituted C1-C6 alkyl, where optional substituents are one or more substituents Rx; each dashed line represents an optional additional bond, but when a triple bond exists between the C atom to which R 25 is attached and the C atom to which R 26 and R 27 are attached, then R 25 and either R 26 or R 27 are absent; the Ab segment containing at least one antigen binding site is an antibody or an antigen-binding fragment thereof and is selected from the group consisting of a human antibody, an antigen-binding fragment of a human antibody, a humanized antibody, an antigen-binding fragment of a humanized antibody, a chimeric antibody, an antigen -binding fragment of chimeric antibody, glycosylated antibody and glycosylated antigen binding fragment; and n is the ratio of the [D-(X)b-(AA)w-(L)-] group to the Ab segment containing at least one antigen binding site and ranges from 1 to 12. 3. Konjugat lijeka prema patentnom zahtjevu 1, odabran od formula (IV) i (V): gdje: R19 je odabran od -C1-C8 alkilen-, -O-(C1-C8 alkilen), -C1-C8 alkilen-C6-C12 arilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx i -C6-C12 arilen-C1-C8 alkilen-gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, gdje svaki od iznad navedenih alkilen supstituenata bilo zaseban ili vezan za drugi segment ugljikovog lanca može po izboru biti supstituiran sa jednim ili više supstituenata Rx; M je odabran iz grupe koja se sastoji od -C1-C3 alkilen- i -C1-C3 alkilen-(C5-C7 karbociklo)-; (AA)w je formule (II) gdje valovite linije označavaju točku kovalentnih vezivanja za (X)b ako postoji, ili segment lijeka (valovita linija na lijevo) i za veznik (valovita linija na desno); R21 je, pri svakom pojavljivanju, odabran iz grupe koja se sastoji od vodika, metila, izopropila, sek-butila, benzila, indolilmetila, -(CH2)3NHCONH2,-(CH2)4NH2, -(CH2)3NHC(=NH)NH2 i -(CH2)4NHC(=NH)NH2; w je cijeli broj od 0 do 6; X je grupa za produžavanje odabrana iz grupe koja se sastoji od -CONH-(C2-C4 alkilen)NH-, -COO-CH2-fenilen-NH-, gdje navedena fenilen grupa može po izboru biti supstituirana sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, -CONH-(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkilen)S-, -CONH-(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)S-, -(C2-C4 alkilen)NH- i -(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-; D je segment lijeka formule (Ia) ili formule (lb), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog gdje: R1 je vodik ili metoksi; svaki od R2 i R3 je vodik; R3' je vodik; svaki od R4, R5, R6, R7, R8, R9, R10 i R12 je nezavisno odabran od vodika, supstituiranog i nesupstituiranog metila, supstituiranog i nesupstituiranog izopropila i supstituiranog i nesupstituiranog terc-butila, gdje po izboru supstituenti su jedan ili više supstituenata Rx; svaki od R11 i R13 je vodik; svaki od R15, R16, R17, R17', R18', R24, R24', R25 i R26 je nezavisno odabran iz grupe koja se sastoji od: vodika i supstituiranih ili nesupstituiranih C1-C6 alkil grupa, gdje po izboru supstituenti su odabrani iz grupe koja se sastoji od alkoksi grupa koje imaju od 1 do 6 atoma ugljika, hidroksil grupa, okso grupa, atoma halogena, OCORy, OCOORy, CORy, COORy, OCONRyRz, CONRyRz, NRyRz, NRyCORz, gdje svaki od Ry i Rz je odabran od atoma vodika i alkil grupa koje imaju od 1 do 6 atoma ugljika; R18 je odabran od vodika, C1-C6 alkil grupe koja može po izboru biti supstituirana sa najmanje jednom grupom Rx, i fenil grupe koja je po izboru supstituirana sa jednim ili više supstituenata RX; R27 je atom vodika ili atom hlora; svaka isprekidana linija predstavlja opcionalnu dodatnu vezu, ali kada trostruka veza postoji između C atoma za koji je R25 vezan i C atoma za koji su R26 i R27 vezani, tada R25 i bilo R26 bilo R27 su odsutni; segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je antitijelo ili antigen-vezujući fragment istog, gdje antitijelo ili antigen-vezujući fragment je monoklonsko antitijelo koje se imunospecifično vezuje za antigene stanica raka, virusne antigene, antigene stanica koje proizvode autoimuna antitijela povezana sa autoimunom bolešću, mikrobne antigene, i poželjno monoklonsko antitijelo koje se imunospecifično veže za antigene stanica raka; i n je odnos grupe [D-(X)b-(AA)w-(L)-] gdje L je kao što je definirano u formulama (IV) ili (V) prema segmentu Ab koji sadrži najmanje jedno antigen vezujuće mjesto i u opsegu je od 3 do 8.3. Drug conjugate according to claim 1, selected from formulas (IV) and (V): where: R19 is selected from -C1-C8 alkylene-, -O-(C1-C8 alkylene), -C1-C8 alkylene-C6-C12 arylene- where the arylene group is in one or more rings which may optionally be substituted with one or multiple substituents Rx and -C6-C12 arylene-C1-C8 alkylene-where the arylene group is in one or more rings that can optionally be substituted with one or more substituents Rx, where each of the above-mentioned alkylene substituents is either separate or attached to another the carbon chain segment can optionally be substituted with one or more Rx substituents; M is selected from the group consisting of -C1-C3 alkylene- and -C1-C3 alkylene-(C5-C7 carbocyclo)-; (AA)w is of formula (II) where the wavy lines indicate the point of covalent attachment to (X)b if present, or the drug segment (wavy line to the left) and to the linker (wavy line to the right); R21 is, at each occurrence, selected from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, -(CH2)3NHCONH2,-(CH2)4NH2, -(CH2)3NHC(=NH)NH2 and -(CH2)4NHC(=NH)NH2; w is an integer from 0 to 6; X is an extending group selected from the group consisting of -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, where said phenylene group can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH-COO -CH2-(phenylene which can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkylene)S-, -CONH-(C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, - (C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, -(C2-C4 alkylene)S-, -(C2-C4 alkylene)NH- and -(C2-C4 alkylene)NH-COO-CH2-( phenylene which can optionally be substituted with from one to four substituents Rx selected from the group which consists of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-; D is a drug segment of formula (Ia) or formula (lb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof where: R 1 is hydrogen or methoxy; each of R 2 and R 3 is hydrogen; R3' is hydrogen; each of R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 12 is independently selected from hydrogen, substituted and unsubstituted methyl, substituted and unsubstituted isopropyl and substituted and unsubstituted tert-butyl, wherein optionally the substituents are one or more substituents Rx ; each of R11 and R13 is hydrogen; each of R15, R16, R17, R17', R18', R24, R24', R25 and R26 is independently selected from the group consisting of: hydrogen and substituted or unsubstituted C1-C6 alkyl groups, where optional substituents are selected from the group consisting of alkoxy groups having from 1 to 6 carbon atoms, hydroxyl groups, oxo groups, halogen atoms, OCORy, OCOORy, CORy, COORy , OCONRyRz, CONRyRz, NRyRz, NRyCORz, wherein each of Ry and Rz is selected from hydrogen atoms and alkyl groups having from 1 to 6 carbon atoms; R 18 is selected from hydrogen, a C 1 -C 6 alkyl group which may be optionally substituted with at least one R x group, and a phenyl group which may be optionally substituted with one or more R x substituents; R27 is a hydrogen atom or a chlorine atom; each dashed line represents an optional additional bond, but when a triple bond exists between the C atom to which R25 is attached and the C atom to which R26 and R27 are attached, then R25 and either R26 or R27 are absent; an Ab segment containing at least one antigen-binding site is an antibody or antigen-binding fragment thereof, where the antibody or antigen-binding fragment is a monoclonal antibody that immunospecifically binds to cancer cell antigens, viral antigens, antigens of cells that produce autoimmune antibodies associated with an autoimmune disease , microbial antigens, and preferably a monoclonal antibody that immunospecifically binds to cancer cell antigens; and n is the ratio of the group [D-(X)b-(AA)w-(L)-] where L is as defined in formulas (IV) or (V) to the Ab segment containing at least one antigen binding site and in extent is from 3 to 8. 4. Konjugat lijeka prema patentnom zahtjevu 1, odabran od formula (IV) i (V): gdje: R19 je odabran od -C1-C6 alkilen-, -fenilen-C1-C6 alkilen- gdje fenilen grupa može po izboru biti supstituirana sa jednim ili više supstituenata Rx odabranim iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, gdje svaki od iznad navedenih alkilen supstituenata bilo zaseban bilo vezan za drugi segment u ugljikovom lancu može po izboru biti supstituiran sa jednim ili više supstituenata Rx odabranim iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, aril grupa koje imaju od 6 do 12 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, i poželjno R19 je C1-C6 alkilen grupa; M je -C1-C3 alkilen-(C5-C7 karbociklo)-; w je 0 ili 2, i gdje w je 2, tada (AA)w je formule (III): gdje valovite linije označavaju točku kovalentnih vezivanja za (X)b ako postoji, ili segment lijeka (valovita linija na lijevo) i za veznik (valovita linija na desno); R22 je odabran od metila, benzila, izopropila, sek-butila i indolilmetila; R23 je odabran od metila, -(CH2)4NH2, -(CH2)3NHCONH2 i -(CH2)3NHC(=NH)NH2; X je grupa za produžavanje odabrana iz grupe koja se sastoji od -CONH-(C2-C4 alkilen)NH-, -COO-CH2-fenilen-NH-, gdje navedena fenilen grupa može po izboru biti supstituirana sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, -CONH-(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkilen)S-, -CONH-(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)S-, -(C2-C4 alkilen)NH- i -(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-; D je segment lijeka formule (Ia) ili formule (lb), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog gdje: R1 je vodik ili metoksi; svaki od R2 i R3 je vodik; R3' je vodik; svaki od R5, R7, R8, R9 i R10 je vodik; svaki od R4 i R6 je metil; svaki od R11 i R13 je vodik; R12 je izopropil, terc-butil ili benzil; svaki od R15, R16, R17, R17', R18', R24, R24', R25 i R26 je nezavisno odabran iz grupe koja se sastoji od vodika i C1-C6 alkil grupe, poželjno vodika i metila; R18 je odabran od vodika i fenila, poželjno vodika; R27 je atom vodika ili atom hlora; svaki par ugljika povezan sa jednom ili više isprekidanih linija je vezan preko dvostrukih veza; segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je monoklonsko antitijelo odabrano iz grupe koja se sastoji od Abciksimaba, Alemtuzumaba, Basiliksimaba, Bevacizumaba, Cetuksimaba, Daklizumaba, Glembatumumaba, Gemtuzumaba, Ibritumomaba, Inotuzumaba, Labetuzumaba, Lorvotuzumaba, Milatuzumaba, Nimotuzumaba, Omalizumaba, Palivizumaba, Panitumumaba, Pinatuzumaba, Rituksimaba,Vorsetuzumaba, Trastuzumaba, anti-CD4 antitijela, anti-CD5 antitijela i anti-CD13 antitijela, ili njihovog imunološki aktivnog dijela, i poželjno antitijelo je odabrano od Trastuzumaba, Rituksimaba, anti-CD4 antitijela, anti-CD5 antitijela i anti-CD13 antitijela ili njihovog imunološki aktivnog dijela; i n je odnos grupe [D-(X)b-(AA)w-(L)-] gdje L je kao što je definirano u formulama (IV) ili (V) prema segmentu Ab koji sadrži najmanje jedno antigen vezujuće mjesto i u opsegu je od 3 do 5.4. Drug conjugate according to claim 1, selected from formulas (IV) and (V): where: R19 is selected from -C1-C6 alkylene-, -phenylene-C1-C6 alkylene- where the phenylene group can optionally be substituted with one or more substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms , alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, where each of the above-mentioned alkylene substituents either separately or attached to another segment in the carbon chain can optionally be substituted with one or more substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, aryl groups having from 6 to 12 carbon atoms, halogen atoms, nitro groups and cyano groups, and preferably R19 is a C1-C6 alkylene group; M is -C1-C3 alkylene-(C5-C7 carbocyclo)-; w is 0 or 2, and where w is 2, then (AA)w is of formula (III): where the wavy lines indicate the point of covalent attachment to (X)b if present, or the drug segment (wavy line to the left) and to the linker (wavy line to the right); R 22 is selected from methyl, benzyl, isopropyl, sec-butyl and indolylmethyl; R23 is selected from methyl, -(CH2)4NH2, -(CH2)3NHCONH2 and -(CH2)3NHC(=NH)NH2; X is an extending group selected from the group consisting of -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, where said phenylene group can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH-COO -CH2-(phenylene which can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkylene)S-, -CONH-(C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, - (C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, -(C2-C4 alkylene)S-, -(C2-C4 alkylene)NH- and -(C2-C4 alkylene)NH-COO-CH2-( phenylene which can optionally be substituted with from one to four substituents Rx selected from the group which consists of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-; D is a drug segment of formula (Ia) or formula (lb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof where: R 1 is hydrogen or methoxy; each of R 2 and R 3 is hydrogen; R3' is hydrogen; each of R5, R7, R8, R9 and R10 is hydrogen; each of R 4 and R 6 is methyl; each of R11 and R13 is hydrogen; R 12 is isopropyl, tert-butyl or benzyl; each of R15, R16, R17, R17', R18', R24, R24', R25 and R26 is independently selected from the group consisting of hydrogen and a C1-C6 alkyl group, preferably hydrogen and methyl; R 18 is selected from hydrogen and phenyl, preferably hydrogen; R27 is a hydrogen atom or a chlorine atom; each pair of carbons connected by one or more dashed lines is connected via double bonds; the Ab segment containing at least one antigen binding site is a monoclonal antibody selected from the group consisting of Abciximab, Alemtuzumab, Basiliximab, Bevacizumab, Cetuximab, Daclizumab, Glembatumumab, Gemtuzumab, Ibritumomab, Inotuzumab, Labetuzumab, Lorvotuzumab, Milatuzumab, Nimotuzumab, Omalizumab, Palivizumab , Panitumumab, Pinatuzumab, Rituximab, Vorsetuzumab, Trastuzumab, anti-CD4 antibodies, anti-CD5 antibodies and anti-CD13 antibodies, or an immunologically active part thereof, and the preferred antibody is selected from Trastuzumab, Rituximab, anti-CD4 antibodies, anti-CD5 antibodies and anti-CD13 antibodies or their immunologically active part; and n is the ratio of the group [D-(X)b-(AA)w-(L)-] where L is as defined in formulas (IV) or (V) to the Ab segment containing at least one antigen binding site and in extent is from 3 to 5. 5. Konjugat lijeka prema patentnom zahtjevu 1, odabran od formula (IV) i (V): gdje: R19 je -C3-C6 alkilen-; M je -C1-C3 alkilen-(C5-C7 karbociklo)-; w je 0 ili 2, i gdje w je 2, tada (AA)w je formule (III): gdje R22 je izopropil, R23 je-(CH2)3NHCONH2, gdje valovite linije označavaju točku kovalentnih vezivanja za (X)b ako postoji, ili segment lijeka (valovita linija na lijevo) i za veznik (valovita linija na desno); X je grupa za produžavanje odabrana iz grupe koja se sastoji od -CONH-(C2-C4 alkilen)NH-, -COO-CH2-fenilen-NH-, gdje navedena fenilen grupa može po izboru biti supstituirana sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, -CONH-(C2-C4 alkilen)NH- COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkilen)S-, -CONH-(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)S-, -(C2-C4 alkilen)NH- i -(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-; D je segment lijeka formule (Ia) ili formule (lb), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog odabran iz slijedeće grupe:5. Drug conjugate according to claim 1, selected from formulas (IV) and (V): where: R19 is -C3-C6 alkylene-; M is -C1-C3 alkylene-(C5-C7 carbocyclo)-; w is 0 or 2, and where w is 2, then (AA)w is of formula (III): where R 22 is isopropyl, R 23 is -(CH 2 ) 3 NHCONH 2 , where the wavy lines indicate the point of covalent attachment to (X)b if present, or the drug segment (wavy line to the left) and to the linker (wavy line to the right); X is an extending group selected from the group consisting of -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, where said phenylene group can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH- COO -CH2-(phenylene which can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkylene)S-, -CONH-(C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, - (C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, -(C2-C4 alkylene)S-, -(C2-C4 alkylene)NH- and -(C2-C4 alkylene)NH-COO-CH2-( phenylene which can optionally be substituted with from one to four substituents Rx selected from the group which consists of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-; D is a drug segment of formula (Ia) or formula (lb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof selected from the following group: gdje valovite linije označavaju točku kovalentnog vezivanja za (X)b ako postoji, ili (AA)w ako postoji, ili vezujuću grupu L; segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je odabran od Trastuzumaba, Rituksimaba, anti-CD4 antitijela, anti-CD5 antitijela i anti-CD13 antitijela ili njihovog imunološki aktivnog dijela; i n je odnos grupe [D-(X)b-(AA)w-(L)-] gdje L je kao što je definirano u formulama (IV) ili (V) prema segmentu Ab koji sadrži najmanje jedno antigen vezujuće mjesto i u opsegu je od 3 do 5.where the wavy lines indicate the point of covalent attachment to (X)b if present, or (AA)w if present, or the linking group L; the Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab, anti-CD4 antibodies, anti-CD5 antibodies and anti-CD13 antibodies or an immunologically active part thereof; and n is the ratio of the group [D-(X)b-(AA)w-(L)-] where L is as defined in formulas (IV) or (V) to the Ab segment containing at least one antigen binding site and in extent is from 3 to 5. 6. Konjugat lijeka prema patentnom zahtjevu 5, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je odabran od Trastuzumaba, Rituksimaba i anti-CD4 antitijela ili njihovog imunološki aktivnog dijela.6. Drug conjugate according to patent claim 5, where the Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab and anti-CD4 antibodies or their immunologically active part. 7. Konjugat lijeka prema patentnom zahtjevu 5, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je Trastuzumab ili njegov imunološki aktivan dio.7. Drug conjugate according to claim 5, where the Ab segment containing at least one antigen binding site is Trastuzumab or its immunologically active part. 8. Konjugat lijeka prema patentnom zahtjevu 1, odabran od formula (IV) i (V): gdje: R19 je -C3-C6 alkilen-; M je -C1-C3 alkilen-(C5-C7 karbociklo)-; w je 0 ili 2, i gdje w je 2, tada (AA)w je formule (III): gdje R22 je izopropil, R23 je-(CH2)3NHCONH2, a valovite linije označavaju točku kovalentnih vezivanja za (X)b ako postoji, ili segment lijeka (valovita linija na lijevo) i za veznik (valovita linija na desno); X je grupa za produžavanje odabrana iz grupe koja se sastoji od -CONH-(C2-C4 alkilen)NH-, -COO-CH2-fenilen-NH-, gdje navedena fenilen grupa može po izboru biti supstituirana sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, -CONH-(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkilen)S-, -CONH-(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)-NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)S-, -(C2-C4 alkilen)NH- i -(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-; D je segment lijeka formule (Ia) ili formule (lb), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog odabran od:8. Drug conjugate according to claim 1, selected from formulas (IV) and (V): where: R19 is -C3-C6 alkylene-; M is -C1-C3 alkylene-(C5-C7 carbocyclo)-; w is 0 or 2, and where w is 2, then (AA)w is of formula (III): where R 22 is isopropyl, R 23 is -(CH 2 ) 3 NHCONH 2 , and wavy lines indicate the point of covalent attachment to (X)b if present, or the drug segment (wavy line to the left) and to the linker (wavy line to the right); X is an extending group selected from the group consisting of -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, where said phenylene group can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH-COO -CH2-(phenylene which can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkylene)S-, -CONH-(C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, - (C2-C4 alkylene)-NHCO(C1-C3 alkylene)S-, -(C2-C4 alkylene)S-, -(C2-C4 alkylene)NH- and -(C2-C4 alkylene)NH-COO-CH2- (phenylene which can optionally be substituted with from one to four substituents Rx selected from the group which consists of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-; D is a drug segment of formula (Ia) or formula (lb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof selected from: gdje valovite linije označavaju točku kovalentnog vezivanja za (X)b ako postoji, ili (AA)w ako postoji, ili vezujuću grupu L; segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je odabran od Trastuzumaba, Rituksimaba, anti-CD4 antitijela, anti-CD5 antitijela i anti-CD13 antitijela ili njihovog imunološki aktivnog dijela; i n je odnos grupe [D-(X)b-(AA)w-(L)-] gdje L je kao što je definirano u formulama (IV) ili (V) prema segmentu koji sadrži najmanje jedno antigen vezujuće mjesto i u opsegu je od 3 do 5.where the wavy lines indicate the point of covalent attachment to (X)b if present, or (AA)w if present, or the linking group L; the Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab, anti-CD4 antibodies, anti-CD5 antibodies and anti-CD13 antibodies or an immunologically active part thereof; and n is the ratio of the group [D-(X)b-(AA)w-(L)-] where L is as defined in formulas (IV) or (V) to the segment containing at least one antigen binding site and is in the range from 3 to 5. 9. Konjugat lijeka prema patentnom zahtjevu 4 ili patentnom zahtjevu 8, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je odabran od Trastuzumaba, Rituksimaba i anti-CD4 antitijela ili njihovog imunološki aktivnog dijela.9. Drug conjugate according to claim 4 or claim 8, where the Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab and anti-CD4 antibodies or their immunologically active part. 10. Konjugat lijeka prema patentnom zahtjevu 4 ili patentnom zahtjevu 8, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je Trastuzumab ili njegov imunološki aktivni dio.10. Drug conjugate according to claim 4 or claim 8, where the Ab segment containing at least one antigen binding site is Trastuzumab or its immunologically active part. 11. Konjugat lijeka prema patentnom zahtjevu 1, formule (IV): gdje: R19 je -C5 alkilen-; b je 1; w je 0 ili 2, i gdje w je 2, tada (AA)w je formule (III): gdje R22 je izopropil, R23 je -(CH2)3NHCONH2, a valovite linije označavaju točku kovalentnih vezivanja za (X)b ako postoji, ili segment lijeka (valovita linija na lijevo) i za veznik (valovita linija na desno); i X je grupa za produžavanje odabrana od -CONH(CH2)3NHCOOCH2-fenilen-NH- i -CONH(CH2)3NH-;ili formule (V) gdje M je -metil-cikloheksilen-; b je 1; w je 0; i X je grupa za produžavanje odabrana od -CONH(CH2)3-S- i -CONH(CH2)3NHCO(CH2)2S-; D je segment lijeka formule (la), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog odabran od:11. Drug conjugate according to claim 1, formula (IV): where: R19 is -C5 alkylene-; b is 1; w is 0 or 2, and where w is 2, then (AA)w is of formula (III): where R 22 is isopropyl, R 23 is -(CH 2 ) 3 NHCONH 2 , and the wavy lines indicate the point of covalent attachment to (X)b if present, or the drug segment (wavy line to the left) and to the linker (wavy line to the right); and X is an extending group selected from -CONH(CH2)3NHCOOCH2-phenylene-NH- and -CONH(CH2)3NH-; or formula (V) where M is -methyl-cyclohexylene-; b is 1; w is 0; and X is an extending group selected from -CONH(CH2)3-S- and -CONH(CH2)3NHCO(CH2)2S-; D is a drug segment of formula (la), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof selected from: gdje valovite linije označavaju točku kovalentnog vezivanja za (X)b ako postoji, ili (AA)w ako postoji, ili vezujuću grupu L; segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je je odabran od Trastuzumaba, Rituksimaba, anti-CD4 antitijela, anti-CD5 antitijela i anti-CD13 antitijela ili njihovog imunološki aktivnog dujela; i n je odnos grupe [D-(X)b-(AA)w-(L)-] gdje L je kao što je definirano u formulama (IV) ili (V) prema segmentu koji sadrži najmanje jedno antigen vezujuće mjesto i u opsegu je od 3 do 5, i poželjno 4.where the wavy lines indicate the point of covalent attachment to (X)b if present, or (AA)w if present, or the linking group L; an Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab, anti-CD4 antibodies, anti-CD5 antibodies and anti-CD13 antibodies or an immunologically active portion thereof; and n is the ratio of the group [D-(X)b-(AA)w-(L)-] where L is as defined in formulas (IV) or (V) to the segment containing at least one antigen binding site and is in the range from 3 to 5, and preferably 4. 12. Konjugat lijeka prema patentnom zahtjevu 11, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je odabran od Trastuzumaba, Rituksimaba i anti-CD4 antitijela ili njihovog imunološki aktivnog dijela.12. Drug conjugate according to claim 11, where the Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab and anti-CD4 antibodies or their immunologically active part. 13. Konjugat lijeka prema patentnom zahtjevu 11, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je Trastuzumab ili njegov imunološki aktivan dio.13. Drug conjugate according to claim 11, where the Ab segment containing at least one antigen binding site is Trastuzumab or its immunologically active part. 14. Konjugat lijeka prema patentnom zahtjevu 1, formule (IV): gdje R19 je -C5 alkilen-; b je 1; w je 0 ili 2, i gdje w je 2, tada (AA)w je formule (III): gdje R22 je izopropil, R23 je-(CH2)3NHCONH2, a valovite linije označavaju točku kovalentnih vezivanja za (X)b ako postoji, ili segment lijeka (valovita linija na lijevo) i za veznik (valovita linija na desno); i X je grupa za produžavanje odabrana od -(CH2)3NHCOOCH2-fenilen-NH-, i --(CH2)3NH-; ili formule (V) gdje M je -metil-cikloheksilen-; b je 1; w je 0; i X je grupa za produžavanje odabrana od -(CH2)3S- i -(CH2)3NHCO(CH2)2S-; D je segment lijeka formule (Ib), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog odabran od:14. Drug conjugate according to patent claim 1, formula (IV): where R19 is -C5 alkylene-; b is 1; w is 0 or 2, and where w is 2, then (AA)w is of formula (III): where R 22 is isopropyl, R 23 is -(CH 2 ) 3 NHCONH 2 , and wavy lines indicate the point of covalent attachment to (X)b if present, or the drug segment (wavy line to the left) and to the linker (wavy line to the right); and X is an extending group selected from -(CH 2 ) 3 NHCOOCH 2 -phenylene-NH-, and --(CH 2 ) 3 NH-; or formula (V) where M is -methyl-cyclohexylene-; b is 1; w is 0; and X is an extending group selected from -(CH2)3S- and -(CH2)3NHCO(CH2)2S-; D is a drug segment of formula (Ib), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof selected from: gdje valovite linije označavaju točku kovalentnog vezivanja za (X)b ako postoji, ili (AA)w ako postoji, ili vezujuću grupu L; segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je odabran od Trastuzumaba, Rituksimaba, anti-CD4 antitijela, anti-CD5 antitijela i anti-CD13 antitijela ili njihovog imunološki aktivnog dijela; i n je odnos grupe [D-(X)b-(AA)w-(L)-] gdje L je kao što je definirano u (IV) ili (V) prema segmentu koji sadrži najmanje jedno antigen vezujuće mjesto i u opsegu je od 3 do 5, i poželjno 4.where the wavy lines indicate the point of covalent attachment to (X)b if present, or (AA)w if present, or the linking group L; the Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab, anti-CD4 antibodies, anti-CD5 antibodies and anti-CD13 antibodies or an immunologically active part thereof; and n is the ratio of the group [D-(X)b-(AA)w-(L)-] where L is as defined in (IV) or (V) to a segment containing at least one antigen binding site and is in the range of 3 to 5, and preferably 4. 15. Konjugat lijeka prema patentnom zahtjevu 14, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je odabran od Trastuzumaba, Rituksimaba i anti-CD4 antitijela ili njihovog imunološki aktivnog dijela.15. Drug conjugate according to patent claim 14, where the Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab and anti-CD4 antibodies or their immunologically active part. 16. Konjugat lijeka prema patentnom zahtjevu 14, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je Trastuzumab ili njegov imunološki aktivan dio.16. Drug conjugate according to claim 14, where the Ab segment containing at least one antigen binding site is Trastuzumab or an immunologically active part thereof. 17. Antitijelo lijek konjugat prema patentnom zahtjevu 11, odabran iz grupe koja se sastoji od:17. Antibody drug conjugate according to claim 11, selected from the group consisting of: gdje svaki od je odabran od Trastuzumaba, Rituksimaba, anti-CD4 antitijela, anti-CD5 antitijela i anti-CD13 antitijela ili njihovog imunološki aktivnog dijela.where each of is selected from Trastuzumab, Rituximab, anti-CD4 antibodies, anti-CD5 antibodies and anti-CD13 antibodies or an immunologically active portion thereof. 18. Konjugat lijeka prema patentnom zahtjevu 8, odabran iz grupe koja se sastoji od:18. Drug conjugate according to claim 8, selected from the group consisting of: gdje svaki od je odabran od Trastuzumaba, Rituksimaba, anti-CD4 antitijela, anti-CD5 antitijela i anti-CD13 antitijela ili njihovog imunološki aktivnog dijela.where each of is selected from Trastuzumab, Rituximab, anti-CD4 antibodies, anti-CD5 antibodies and anti-CD13 antibodies or their immunologically active part. 19. Konjugat lijeka prema patentnom zahtjevu 17 ili patentnom zahtjevu 18, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je odabran od Trastuzumaba, Rituksimaba i anti-CD4 antitijela ili njihovog imunološki aktivnog dijela.19. Drug conjugate according to patent claim 17 or patent claim 18, where the Ab segment containing at least one antigen binding site is selected from Trastuzumab, Rituximab and anti-CD4 antibodies or their immunologically active part. 20. Konjugat lijeka prema patentnom zahtjevu 17 ili patentnom zahtjevu 18, gdje segment Ab koji sadrži najmanje jedno antigen vezujuće mjesto je Trastuzumab ili njegov imunološki aktivan dio.20. Drug conjugate according to patent claim 17 or patent claim 18, where the Ab segment containing at least one antigen binding site is Trastuzumab or its immunologically active part. 21. Spoj formule D-X-(AA)w-L1 ili formule D-X-(AA)w-H, gdje: L1 je veznik odabran iz grupe formula koja se sastoji od:21. Compound of formula D-X-(AA)w-L1 or formula D-X-(AA)w-H, where: L1 is a conjunction selected from a group of formulas consisting of: gdje svaka od valovitih linija označava točku kovalentnog vezivanja za (AA)w ako postoji, ili za X; G je odabran od halo, -O-mezil i-O-tozil; J je odabran od halo, hidroksi, -N-sukcinimidoksi, -O-(4-nitrofenil), -O-pentafluorofenil, -O-tetrafluorofenil i -O-C(O)-OR20; R19 je odabran od -C1-C12 alkilen-, -C3-C8 karbociklo, -O-(C1-C12 alkilen), -C6-C18 arilen u jednom ili više prstenova koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx, -C1-C12 alkilen-C6-C18 arilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, - C6-C18 arilen-C1-C12 alkilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, -C1-C12 alkilen-(C3-C8 karbociklo)-, -(C3-C8 karbociklo)-C1-C12 alkilen-, -C5-C14 heterociklo- gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -C1-C12 alkilen-(C5-C14 heterociklo)- gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -(C5-C14 heterociklo)-C1-C12 alkilen-, gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu je navedena grupa po izboru supstituirana sa jednim ili više supstituenata Rx, -(OCH2CH2)r- i -CH2-(OCH2CH2)r-, gdje svaki od gore navedenih alkilen supstituenata bilo zaseban ili vezan za drugi segment ugljikovog lanca može po izboru biti supstituiran sa jednim ili više supstituenata Rx; R20 je C1-C12 alkil ili aril grupa koja ima od 6 do 18 atoma ugljika u jednom ili više aromatičnih prstenova, pri čemu navedene aril grupe po izboru su supstituirane sa jednim ili više supstituenata Rx; r je cijeli broj u opsegu od 1-10; i svaki od D, X, AA i w je kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 20. where each of the wavy lines indicates the point of covalent attachment to (AA)w if present, or to X; G is selected from halo, -O-mesyl and -O-tosyl; J is selected from halo, hydroxy, -N-succinimidoxy, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR 2 O; R19 is selected from -C1-C12 alkylene-, -C3-C8 carbocyclo, -O-(C1-C12 alkylene), -C6-C18 arylene in one or more rings which can optionally be substituted with one or more substituents Rx, -C1-C12 alkylene-C6-C18 arylene- where the arylene group is in one or more rings which can optionally be substituted with one or more substituents Rx, - C6-C18 arylene-C1-C12 alkylene- where the arylene group is in one or several rings which can optionally be substituted with one or more substituents Rx, -C1-C12 alkylene-(C3-C8 carbocyclo)-, -(C3-C8 carbocyclo)-C1-C12 alkylene-, -C5-C14 heterocyclo- where said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -C1-C12 alkylene-(C5-C14 heterocyclo)- where the specified heterocyclo group can be a saturated or unsaturated group k which has one or more rings and which contains at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -(C5-C14 heterocyclo)- C1-C12 alkylene-, where said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optional substituted with one or more substituents Rx, -(OCH2CH2)r- and -CH2-(OCH2CH2)r-, where each of the above-mentioned alkylene substituents either separately or attached to another segment of the carbon chain can optionally be substituted with one or more substituents Rx; R20 is a C1-C12 alkyl or aryl group having from 6 to 18 carbon atoms in one or more aromatic rings, wherein said aryl groups are optionally substituted with one or more substituents Rx; r is an integer in the range of 1-10; and each of D, X, AA and w is as defined in any one of claims 1 to 20. 22. Spoj formule D-X-(AA)w-L1 ili formule D-X-(AA)w-H prema patentnom zahtjevu 21, gdje: L1 je veznik formule: gdje: valovita linija označava točku kovalentnog vezivanja za (AA)w ako postoji, ili za X; R19 je odabran od -C1-C12 alkilen-, -O-(C1-C12 alkilen), -C6-C12 arilen u jednom ili više prstenova koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx, -C1-C12 alkilen-C6-C12 arilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, -C6-C12 arilen-C1-C12 alkilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, -C5-C12 heterociklo- gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu navedena grupa po izboru je supstituirana sa jednim ili više supstituenata Rx, -C1-C12 alkilen-(C5-C12 heterociklo)- gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu navedena grupa po izboru je supstituirana sa jednim ili više supstituenata Rx, -(C5-C12 heterociklo)-C1-C12 alkilen-gdje navedena heterociklo grupa može biti zasićena ili nezasićena grupa koja ima jedan ili više prstenova i koja sadrži najmanje jedan atom kisika, dušika ili sumpora u navedenom(im) prstenu(ovima), pri čemu navedena grupa po izboru je supstituirana sa jednim ili više supstituenata Rx, -(OCH2CH2)r- i -CH2-(OCH2CH2)r-, gdje svaki od iznad navedenih alkilen supstituenata bilo zaseban ili vezan za drugi segment ugljikovog lanca može po izboru biti supstituiran sa jednim ili više supstituenata Rx; r je cijeli broj u opsegu od 1-6; i svaki od D, X, AA i w je kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 20.22. Compound of formula D-X-(AA)w-L1 or formula D-X-(AA)w-H according to claim 21, where: L1 is the conjunction of the formula: where: the wavy line indicates the point of covalent attachment to (AA)w if present, or to X; R19 is selected from -C1-C12 alkylene-, -O-(C1-C12 alkylene), -C6-C12 arylene in one or more rings which can optionally be substituted with one or more substituents Rx, -C1-C12 alkylene- C6-C12 arylene- where the arylene group is in one or more rings which can optionally be substituted with one or more substituents Rx, -C6-C12 arylene-C1-C12 alkylene- where the arylene group is in one or more rings which can to be optionally substituted with one or more substituents Rx, -C5-C12 heterocyclo- where the said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in the said ring(s) these), wherein said group is optionally substituted with one or more substituents Rx, -C1-C12 alkylene-(C5-C12 heterocyclo)- where said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one oxygen, nitrogen or sulfur atom in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -(C5-C12 heterocyclo)-C1-C12 alkylene-where said heterocyclo group can be a saturated or unsaturated group having one or more rings and containing at least one atom of oxygen, nitrogen or sulfur in said ring(s), wherein said group is optionally substituted with one or more substituents Rx, -(OCH2CH2)r- and -CH2- (OCH2CH2)r-, where each of the above-mentioned alkylene substituents, whether separate or attached to another segment of the carbon chain, can optionally be substituted with one or more substituents Rx; r is an integer in the range of 1-6; and each of D, X, AA and w is as defined in any one of claims 1 to 20. 23. Spoj formule D-X-(AA)w-L1 ili formule D-X-(AA)w-H prema patentnom zahtjevu 21 gdje: L1 je veznik formule: gdje: valovita linija označava točku kovalentnog vezivanja za (AA)w ako postoji, ili za X; R19 je odabran od -C1-C8 alkilen-, -O-(C1-C8 alkilen), -C1-C3 alkilen-C6-C12 arilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, -C6-C12 arilen-C1-C8 alkilen- gdje arilen grupa je u jednom ili više prstenova koja može po izboru biti supstituirana sa jednim ili više supstituenata Rx, gdje svaki od iznad navedenih alkilen supstituenata bilo zaseban ili vezan za drugi segment ugljikovog lanca može po izboru biti supstituiran sa jednim ili više supstituenata Rx; (AA)w je formule (II): gdje valovite linije označavaju točku kovalentnih vezivanja za X (valovita linija na lijevo) i za L1 ili za atom vodika (valovita linija na desno); gdje R21 je odabran, pri svakom pojavljivanju, iz grupe koja se sastoji od vodika, metila, izopropila, sek-butila, benzila, indolilmetila, -(CH2)3NHCONH2,-(CH2)4NH2, - (CH2)3NHC(=NH)NH2 i -(CH2)4NHC-(=NH)NH2, i w je cijeli broj od 0 do 6; X je grupa za produžavanje odabrana iz grupe koja se sastoji od -CONH-(C2-C4 alkilen)NH-,-COO-CH2-fenilen-NH, gdje navedena fenilen grupa može po izboru biti supstituirana sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, -CONH-(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkilen)S-, -CONH-(C2-C4 alkilen)-NHCO(CrC3 alkilen)S-, -(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)S-, -(C2-C4 alkilen)NH- i -(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-; i D je segment lijeka formule (Ia) ili formule (lb), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog:23. Compound of formula D-X-(AA)w-L1 or formula D-X-(AA)w-H according to claim 21 where: L1 is the conjunction of the formula: where: the wavy line indicates the point of covalent attachment to (AA)w if present, or to X; R19 is selected from -C1-C8 alkylene-, -O-(C1-C8 alkylene), -C1-C3 alkylene-C6-C12 arylene- where the arylene group is in one or more rings which can optionally be substituted with one or more substituents Rx, -C6-C12 arylene-C1-C8 alkylene- where the arylene group is in one or more rings which can optionally be substituted with one or more substituents Rx, where each of the above-mentioned alkylene substituents either separately or attached to another segment of the carbon chain can optionally substituted with one or more Rx substituents; (AA)w is of formula (II): where the wavy lines indicate the point of covalent bonds to X (wavy line to the left) and to L1 or to the hydrogen atom (wavy line to the right); wherein R21 is selected, at each occurrence, from the group consisting of hydrogen, methyl, isopropyl, sec-butyl, benzyl, indolylmethyl, -(CH2)3NHCONH2,-(CH2)4NH2, -(CH2)3NHC(=NH) NH2 and -(CH2)4NHC-(=NH)NH2, and w is an integer from 0 to 6; X is an extending group selected from the group consisting of -CONH-(C2-C4 alkylene)NH-,-COO-CH2-phenylene-NH, where said phenylene group can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH-COO- CH2-(phenylene which can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-, -COCH2NH-COCH2-NH-, -CONH-(C2-C4 alkylene)S-, -CONH-(C2-C4 alkylene)-NHCO(CrC3 alkylene)S-, -(C2 -C4 alkylene)NHCO(C1-C3 alkylene)S-, -(C2-C4 alkylene)S-, -(C2-C4 alkylene)NH- and -(C2-C4 alkylene)NH-COO-CH2-(phenylene which may optionally be substituted with from one to four substituents Rx selected from the group that consists of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-; and D is a drug segment of formula (Ia) or formula (lb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof: gdje valovite linije od (Ia) i (Ib) označavaju točku kovalentnog vezivanja za X; A je odabran od gdje valovite linije segmenta A označavaju točku kovalentnog vezivanja za ostatak segmenta lijeka; R1 je odabran od vodika, ORa i OCORa, gdje Ra je odabran od vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; R2 i R3 su svaki nezavisno odabrani od vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; R3' je odabran od vodika, CORa, i supstituiranog ili nesupstituiranog C1-C6 alkila, gdje Ra je supstituiran ili nesupstituisan C1-C6 alkil, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; svaki od R4, R5, R6, R7, R8, R9, R10 i R12 je nezavisno odabran od vodika i supstituiranog i nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; svaki od R11 i R13 je nezavisno odabran od vodika i supstituiranog ili nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; svaki od R15, R16, R17, R17', R18', R24, R24', R25 i R26 je nezavisno odabran iz grupe koja se sastoji od: vodika i supstituiranih ili nesupstituiranih C1-C6 alkil grupa gdje opcionalni supstituenti su odabrani iz grupe koja se sastoji od alkoksi grupa koje imaju od 1 do 6 atoma ugljika, hidroksil grupa, okso grupa, atoma halogena, OCORy, OCOORy, CORy, COORy, OCONRyRz, CONRyRz, NRyRz, NRyCORz gdje svaki od Ry i Rz je odabran od atoma vodika i alkil grupa koje imaju od 1 do 6 atoma ugljika. R18 je odabran od vodika, C1-C6 alkil grupe koja može po izboru biti supstituirana sa najmanje jednom grupom Rx, i fenil grupe koja je po izboru supstituirana sa jednim ili više supstituenata RX; R27 je odabran od vodika, halogena i supstituiranog ili nesupstituiranog C1-C6 alkila, gdje opcionalni supstituenti su jedan ili više supstituenata Rx; i svaka isprekidana linija predstavlja opcijsku dodatnu vezu, ali kada trostruka veza postoji između C atoma za koji R25 je vezan i C atoma za koji R26 i R27 su vezani, tada R25 i bilo R26 bilo R27 su odsutni.where the wavy lines of (Ia) and (Ib) indicate the point of covalent attachment to X; A is selected from where the wavy lines of segment A indicate the point of covalent attachment to the rest of the drug segment; R1 is selected from hydrogen, ORa and OCORa, where Ra is selected from hydrogen and substituted or unsubstituted C1-C6 alkyl, where optional substituents are one or more substituents Rx; R2 and R3 are each independently selected from hydrogen and substituted or unsubstituted C1-C6 alkyl, wherein optional substituents are one or more substituents Rx; R3' is selected from hydrogen, CORa, and substituted or unsubstituted C1-C6 alkyl, wherein Ra is substituted or unsubstituted C1-C6 alkyl, wherein optional substituents are one or more substituents Rx; each of R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 12 is independently selected from hydrogen and substituted and unsubstituted C 1 -C 6 alkyl, wherein optional substituents are one or more substituents R x ; each of R11 and R13 is independently selected from hydrogen and substituted or unsubstituted C1-C6 alkyl, wherein optional substituents are one or more substituents Rx; each of R15, R16, R17, R17', R18', R24, R24', R25 and R26 is independently selected from the group consisting of: hydrogen and substituted or unsubstituted C1-C6 alkyl groups where the optional substituents are selected from the group consisting of alkoxy groups having from 1 to 6 carbon atoms, hydroxyl groups, oxo groups, halogen atoms, OCORy, OCOORy, CORy, COORy, OCONRyRz , CONRyRz, NRyRz, NRyCORz where each of Ry and Rz is selected from hydrogen atoms and alkyl groups having from 1 to 6 carbon atoms. R 18 is selected from hydrogen, a C 1 -C 6 alkyl group which may be optionally substituted with at least one R x group, and a phenyl group which may be optionally substituted with one or more R x substituents; R27 is selected from hydrogen, halogen and substituted or unsubstituted C1-C6 alkyl, where optional substituents are one or more substituents Rx; and each dashed line represents an optional additional bond, but when a triple bond exists between the C atom to which R 25 is attached and the C atom to which R 26 and R 27 are attached, then R 25 and either R 26 or R 27 are absent. 24. Spoj formule D-X-(AA)w-L1 ili formule D-X-(AA)w-H prema patentnom zahtjevu 21 gdje: L1 je grupa formule: gdje: valovita linija označava točku kovalentnog vezivanja za (AA)w ako postoji, ili za X; R19 je odabran od -C1-C6 alkilen-, fenilen-C1-C6 alkilen- gdje fenilen grupa može po izboru biti supstituirana sa jednim ili više supstituenata Rx odabranim iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, gdje svaki od iznad navedenih alkilen supstituenata bilo zaseban ili vezan za drugi segment u ugljikovom lancu može po izboru biti supstituiran sa jednim ili više supstituenata Rx odabranim iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, aril grupa koje imaju od 6 do 12 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, i poželjno R19 je C1-C6 alkilen grupa; w je 0 ili 2, i gdje w je 2, tada (AA)w je formule (III): gdje valovite linije označavaju točku kovalentnih vezivanja za X (valovita linija na lijevo) i za L1 ili za atom vodika (valovita linija na desno); R22 je odabran od metila, benzila, izopropila, sek-butila i indolilmetila; R23 je odabran od metila, -(CH2)4NH2, -(CH2)3NHCONH2 i -(CH2)3NHC(=NH)NH2; X je grupa za produžavanje odabrana od -CONH-(C2-C4 alkilen)NH-, -CONH(C2-C4 alkilen)NHCOO-CH2-(fenilen koji može po izboru biti supstituiran sa jednim ili više supstituenata Rx odabranim iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH, -CONH-(C2-C4 alkilen)S-, -CONH-(C2-C4 alkilen)NHCO-(C1-C3 alkilen)S-, -(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)S-, -(C2-C4 alkilen)NH- i -(C2-C4 alkilen)NH- COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-; i D je segment lijeka formule (Ia) ili formule (lb), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog:24. Compound of formula D-X-(AA)w-L1 or formula D-X-(AA)w-H according to claim 21 where: L1 is the formula group: where: the wavy line indicates the point of covalent attachment to (AA)w if present, or to X; R19 is selected from -C1-C6 alkylene-, phenylene-C1-C6 alkylene- where the phenylene group can optionally be substituted with one or more substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, Alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, where each of the above-mentioned alkylene substituents either separately or attached to another segment in the carbon chain can optionally be substituted with one or more Rx substituents selected from groups consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, aryl groups having from 6 to 12 carbon atoms, halogen atoms, nitro groups and cyano groups, and preferably R19 is a C1-C6 alkylene group; w is 0 or 2, and where w is 2, then (AA)w is of formula (III): where the wavy lines indicate the point of covalent bonds to X (wavy line to the left) and to L1 or to the hydrogen atom (wavy line to the right); R 22 is selected from methyl, benzyl, isopropyl, sec-butyl and indolylmethyl; R23 is selected from methyl, -(CH2)4NH2, -(CH2)3NHCONH2 and -(CH2)3NHC(=NH)NH2; X is an extending group selected from -CONH-(C2-C4 alkylene)NH-, -CONH(C2-C4 alkylene)NHCOO-CH2-(phenylene which may optionally be substituted with one or more substituents Rx selected from the group consisting of consists of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH, -CONH-(C2-C4 alkylene)S-, -CONH -(C2-C4 alkylene)NHCO-(C1-C3 alkylene)S-, -(C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, -(C2-C4 alkylene)S-, -(C2-C4 alkylene)NH- and -(C2-C4 alkylene)NH-COO-CH2-(phenylene which can optionally be substituted with one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms , alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-; and D is a drug segment of formula (Ia) or formula (lb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof: gdje valovite linije od (Ia) i (Ib) označavaju točku kovalentnog vezivanja za X; A je odabran od gdje valovite linije segmenta A označavaju točku kovalentnog vezivanja za ostatak segmenta lijeka; R1 je vodik ili metoksi; svaki od R2 i R3 je vodik; R3' je vodik; svaki od R5, R7, R8, R9 i R10 je vodik; svaki od R4 i R6 je metil; R12 je izopropil, terc-butil ili benzil; svaki od R11 i R13 je vodik; svaki od R15, R16, R17, R17', R18', R24, R24', R25 i R26 je nezavisno odabran iz grupe koja se sastoji od vodika i C1-C6 alkil grupe, poželjno vodika i metila; R18 je odabran od vodika i fenila, i poželjno vodika; R27 je vodik ili halogen; i svaka isprekidana linija predstavlja opcijsku dodatnu vezu, ali kada trostruka veza postoji između C atoma za koji je R25 vezan i C atoma za koji su R26 i R27 vezani, tada R25 i bilo R26 bilo R27 su odsutni.where the wavy lines of (Ia) and (Ib) indicate the point of covalent attachment to X; A is selected from where the wavy lines of segment A indicate the point of covalent attachment to the rest of the drug segment; R 1 is hydrogen or methoxy; each of R 2 and R 3 is hydrogen; R3' is hydrogen; each of R5, R7, R8, R9 and R10 is hydrogen; each of R 4 and R 6 is methyl; R 12 is isopropyl, tert-butyl or benzyl; each of R11 and R13 is hydrogen; each of R15, R16, R17, R17', R18', R24, R24', R25 and R26 is independently selected from the group consisting of hydrogen and a C1-C6 alkyl group, preferably hydrogen and methyl; R 18 is selected from hydrogen and phenyl, and preferably hydrogen; R27 is hydrogen or halogen; and each dashed line represents an optional additional bond, but when a triple bond exists between the C atom to which R 25 is attached and the C atom to which R 26 and R 27 are attached, then R 25 and either R 26 or R 27 are absent. 25. Spoj formule D-X-(AA)w-L1 ili formule D-X-(AA)w-H prema patentnom zahtjevu 21 gdje: L1 je veznik formule: gdje: valovita linija označava točku kovalentnog vezivanja za (AA)w ako postoji, ili za X; R19 je -C3-C6 alkilen-; w je 0 ili 2, i gdje w je 2, tada (AA)w je formule (III): R22 je izopropil, R23 is-(CH2)3NHCONH2, gdje valovite linije označavaju točku kovalentnih vezivanja za X (valovita linija na lijevo) i za L1 ili za atom vodika (valovita linija na desno); X je grupa za produžavanje odabrana iz grupe koja se sastoji od -CONH-(C2-C4 alkilen)NH-, -COO-CH2-fenilen-NH-, gdje navedena fenilen grupa može po izboru biti supstituirana sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa, -CONH-(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-, -CONH-(C2-C4 alkilen)S-, -CONH-(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)NHCO(C1-C3 alkilen)S-, -(C2-C4 alkilen)S-, -(C2-C4 alkilen)NH- i -(C2-C4 alkilen)NH-COO-CH2-(fenilen koji može po izboru biti supstituiran sa od jednim do četiri supstituenta Rx odabrana iz grupe koja se sastoji od alkil grupa koje imaju od 1 do 6 atoma ugljika, alkoksi grupa koje imaju od 1 do 6 atoma ugljika, atoma halogena, nitro grupa i cijano grupa)-NH-; i D je segment lijeka formule (Ia) ili formule (lb), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog odabran od slijedeće grupe:25. Compound of formula D-X-(AA)w-L1 or formula D-X-(AA)w-H according to claim 21 where: L1 is the conjunction of the formula: where: the wavy line indicates the point of covalent attachment to (AA)w if present, or to X; R19 is -C3-C6 alkylene-; w is 0 or 2, and where w is 2, then (AA)w is of formula (III): R22 is isopropyl, R23 is -(CH2)3NHCONH2, where the wavy lines indicate the point of covalent bonds to X (wavy line to the left) and to L1 or to the hydrogen atom (wavy line to the right); X is an extending group selected from the group consisting of -CONH-(C2-C4 alkylene)NH-, -COO-CH2-phenylene-NH-, where said phenylene group can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro groups and cyano groups, -CONH-(C2-C4 alkylene)NH-COO -CH2-(phenylene which can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-, -CONH-(C2-C4 alkylene)S-, -CONH-(C2-C4 alkylene)NHCO(C1-C3 alkylene)S-, -(C2-C4 alkylene)NHCO( C1-C3 alkylene)S-, -(C2-C4 alkylene)S-, -(C2-C4 alkylene)NH- and -(C2-C4 alkylene)NH-COO-CH2-(phenylene which can optionally be substituted with from one to four substituents Rx selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, halogen atoms, nitro group and cyano group)-NH-; and D is a drug segment of formula (Ia) or formula (lb), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof selected from the following group: i gdje valovita linija označava točku kovalentnog vezivanja za X.and where the wavy line indicates the point of covalent attachment to X. 26. Spoj formule D-X-(AA)w-L1 ili formule D-X-(AA)w-H prema patentnom zahtjevu 21 gdje: L1 je grupa formule: gdje: valovita linija označava točku kovalentnog vezivanja za (AA)w ako postoji, ili za X; R19 je -C5 alkilen-; w je 0 ili 2, i gdje w je 2, tada (AA)w je formule (III): gdje R22 je izopropil, R23 je-(CH2)3NHCONH2, gdje valovite linije označavaju točku kovalentnih vezivanja za X (valovita linija na lijevo) i za L1 ili za atom vodika (valovita linija na desno); X je grupa za produžavanje odabrana od -CONH(CH2)3NHCOOCH2-fenilen-NH-,-CONH(CH2)3NH-, -CONH(CH2)3-S- i -CONH(CH2)3NHCO(CH2)2S-; i D je segment lijeka formule (Ia), ili farmaceutski prihvatljiva sol, ester, solvat, tautomer ili stereoizomer istog odabran od:26. Compound of formula D-X-(AA)w-L1 or formula D-X-(AA)w-H according to claim 21 where: L1 is the formula group: where: the wavy line indicates the point of covalent attachment to (AA)w if present, or to X; R19 is -C5 alkylene-; w is 0 or 2, and where w is 2, then (AA)w is of formula (III): where R 22 is isopropyl, R 23 is -(CH 2 ) 3 NHCONH 2 , where wavy lines indicate the point of covalent attachment to X (wavy line to the left) and to L1 or to a hydrogen atom (wavy line to the right); X is an extending group selected from -CONH(CH2)3NHCOOCH2-phenylene-NH-, -CONH(CH2)3NH-, -CONH(CH2)3-S- and -CONH(CH2)3NHCO(CH2)2S-; and D is a drug segment of formula (Ia), or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof selected from: gdje valovita linija označava točku kovalentnog vezivanja za X.where the wavy line indicates the point of covalent attachment to X. 27. Spoj formule D-X-(AA)w-L1 prema bilo kojem od patentnih zahtjeva 21 do 26 odabrano od:27. A compound of the formula D-X-(AA)w-L1 according to any one of claims 21 to 26 selected from: i and 28. Spoj formule D-X-(AA)w-H prema bilo kojem od patentnih zahtjeva 21 do 26 odabrano od:28. A compound of the formula D-X-(AA)w-H according to any one of claims 21 to 26 selected from: 29. Konjugat lijeka prema bilo kojem od patentnih zahtjeva 1 do 20, za primjenu kao medikament. 29. Drug conjugate according to any of claims 1 to 20, for use as a medication. 30. Konjugat lijeka prema bilo kojem od patentnih zahtjeva 1 do 20 za primjenu u liječenju raka, i poželjnije raka odabranog od raka pluća, kolorektalnog raka, raka dojke, karcinoma pankreasa, raka bubrega, leukemije, multiplog mijeloma, limfoma i raka ovarija.30. A drug conjugate according to any one of claims 1 to 20 for use in the treatment of cancer, and preferably a cancer selected from lung cancer, colorectal cancer, breast cancer, pancreatic cancer, kidney cancer, leukemia, multiple myeloma, lymphoma and ovarian cancer. 31. Farmaceutska kompozicija koja sadrži konjugat lijeka prema bilo kojem od patentnih zahtjeva 1 do 20 i farmaceutski prihvatljiv nosač.31. A pharmaceutical composition containing a drug conjugate according to any one of claims 1 to 20 and a pharmaceutically acceptable carrier.
HRP20200032TT 2013-05-31 2014-06-02 Antibody drug conjugates HRP20200032T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1309807.4A GB201309807D0 (en) 2013-05-31 2013-05-31 Antibody drug conjugates
PCT/EP2014/061392 WO2014191578A1 (en) 2013-05-31 2014-06-02 Antibody drug conjugates
EP14732514.6A EP3003386B1 (en) 2013-05-31 2014-06-02 Antibody drug conjugates

Publications (1)

Publication Number Publication Date
HRP20200032T1 true HRP20200032T1 (en) 2020-03-20

Family

ID=48805601

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200032TT HRP20200032T1 (en) 2013-05-31 2014-06-02 Antibody drug conjugates

Country Status (31)

Country Link
US (2) US11224663B2 (en)
EP (1) EP3003386B1 (en)
JP (1) JP6412114B2 (en)
KR (2) KR102448393B1 (en)
CN (1) CN105451775B (en)
AR (2) AR096461A1 (en)
AU (1) AU2014273052B2 (en)
BR (1) BR112015029816B1 (en)
CA (1) CA2914041C (en)
CL (1) CL2015003481A1 (en)
CY (1) CY1122662T1 (en)
DK (1) DK3003386T3 (en)
ES (1) ES2778045T3 (en)
GB (1) GB201309807D0 (en)
HR (1) HRP20200032T1 (en)
IL (1) IL242571B (en)
LT (1) LT3003386T (en)
MX (1) MX356431B (en)
MY (1) MY176579A (en)
NZ (1) NZ715646A (en)
PL (1) PL3003386T3 (en)
PT (1) PT3003386T (en)
PY (1) PY1422863A (en)
RS (1) RS59855B1 (en)
RU (1) RU2669812C2 (en)
SG (1) SG11201509563UA (en)
SI (1) SI3003386T1 (en)
SM (1) SMT202000023T1 (en)
UA (1) UA119327C2 (en)
WO (1) WO2014191578A1 (en)
ZA (1) ZA201508487B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089610A1 (en) * 2014-12-06 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
JP6903055B2 (en) * 2015-08-03 2021-07-14 イーエヌビー・セラピューティクス・インク Compositions and Methods for Treating Cancers Associated with ETBR Activation
PE20231050A1 (en) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS FOR THEIR USE
EP3525824A4 (en) * 2016-10-17 2020-06-10 Shenzhen Enduring Biotech, Ltd. MULTI-SPECIFIC LONG-ACTING MOLECULES AND RELATED METHODS
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
KR102491180B1 (en) 2017-04-27 2023-01-20 파르마 마르 에스.에이. Antitumoral compounds
EP3710482A4 (en) * 2017-11-14 2021-08-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS OF MANUFACTURING AND USE OF BISPECIFIC ANTIBODIES
KR102762352B1 (en) * 2017-11-30 2025-02-05 씨젠 인크. Method for preparing drug linker compound
WO2019106608A1 (en) * 2017-12-01 2019-06-06 Abbvie Inc. Anti-cd40 antibody drug conjugates
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
US11564987B2 (en) * 2018-10-21 2023-01-31 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
TWI824043B (en) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 Drug antibody conjugates
JP7590328B2 (en) 2018-12-21 2024-11-26 レゲネロン ファーマシューティカルス，インコーポレーテッド Tubulysin and Protein-Tubulysin Conjugates
KR102501394B1 (en) * 2019-05-02 2023-02-21 주식회사 레고켐 바이오사이언스 Ligand-drug conjugate comprising linker having tris structure
JP2022530482A (en) * 2019-05-02 2022-06-29 レゴケム バイオサイエンシズ， インク． Ligand-drug complex containing a linker with a Tris structure
IL287938B2 (en) * 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody drug conjugates
CA3085001C (en) * 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
US20220265845A1 (en) * 2019-07-31 2022-08-25 Advanced Biodesign Aminothiolester compounds and uses thereof
CN115427081B (en) * 2020-04-21 2025-12-09 法马马有限公司 Pharmaceutical antibody conjugates
CN114262377B (en) * 2021-10-28 2024-03-22 新疆优迈生物技术有限公司 Preparation method of anti-human CD70 nano antibody for blocking binding of CD70 and ligand CD27 thereof and coding sequence thereof
CN115873066A (en) * 2022-07-27 2023-03-31 吉林省博大伟业制药有限公司 A kind of synthetic method of antibody coupling drug linker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545613T3 (en) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatin conjugates and their use in the treatment of cancer, an autoimmune disease or an infectious disease
JP5356648B2 (en) * 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
JP4993645B2 (en) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド Antibody drug conjugates and methods
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
PL2032551T3 (en) * 2006-06-16 2012-01-31 Pharma Mar Sa Antitumoral dihydropyran-2-one compounds
RU2493147C2 (en) 2007-12-20 2013-09-20 Фарма Мар, С.А. Antitumour compounds
LT2294072T (en) 2008-05-23 2017-06-12 Wyeth Llc TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010149688A2 (en) * 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds

Also Published As

Publication number Publication date
ZA201508487B (en) 2017-11-29
WO2014191578A1 (en) 2014-12-04
KR102340681B1 (en) 2021-12-20
CY1122662T1 (en) 2021-03-12
UA119327C2 (en) 2019-06-10
EP3003386A1 (en) 2016-04-13
MX356431B (en) 2018-05-29
KR102448393B1 (en) 2022-09-28
JP6412114B2 (en) 2018-10-24
CA2914041C (en) 2021-12-07
US20220168436A1 (en) 2022-06-02
EP3003386B1 (en) 2019-10-16
NZ715646A (en) 2019-05-31
RU2015156499A3 (en) 2018-03-27
AR096461A1 (en) 2015-12-30
PL3003386T3 (en) 2020-04-30
BR112015029816A2 (en) 2017-07-25
SMT202000023T1 (en) 2020-03-13
JP2016526042A (en) 2016-09-01
PY1422863A (en) 2017-09-01
US11224663B2 (en) 2022-01-18
DK3003386T3 (en) 2020-01-27
CN105451775B (en) 2019-09-06
US12410148B2 (en) 2025-09-09
PT3003386T (en) 2020-01-21
AU2014273052A1 (en) 2016-01-28
RU2015156499A (en) 2017-06-30
IL242571B (en) 2019-10-31
GB201309807D0 (en) 2013-07-17
MX2015016417A (en) 2016-07-05
CA2914041A1 (en) 2014-12-04
MY176579A (en) 2020-08-17
US20160129128A1 (en) 2016-05-12
KR20210156848A (en) 2021-12-27
SG11201509563UA (en) 2015-12-30
AU2014273052B2 (en) 2018-03-08
CN105451775A (en) 2016-03-30
LT3003386T (en) 2020-01-27
RU2669812C2 (en) 2018-10-16
AR123672A2 (en) 2023-01-04
CL2015003481A1 (en) 2016-08-19
SI3003386T1 (en) 2020-03-31
BR112015029816B1 (en) 2022-10-04
KR20160030132A (en) 2016-03-16
RS59855B1 (en) 2020-02-28
ES2778045T3 (en) 2020-08-07

Similar Documents

Publication Publication Date Title
HRP20200032T1 (en) Antibody drug conjugates
HRP20230275T1 (en) Antibody drug conjugates comprising ecteinascidin derivatives
RU2018119296A (en) ANTIBODY CONJUGATES CONTAINING TALL-LIKE RECEPTOR AGONISTS
JP2020019787A5 (en)
JP2019532056A5 (en)
JP2012522512A5 (en)
JP2019520352A5 (en)
RU2014116878A (en) CYTOTOXIC PEPTIDES AND THEIR CONJUGATES ANTIBODY MEDICINE
JP2024075668A (en) Combination of antibody-drug conjugates and tubulin inhibitors
RU2018134331A (en) CONJUGATES ANTIBODY MEDICINES BASED ON ERIBULIN AND METHODS OF APPLICATION
RU2014146951A (en) CONJUGATES TYPE LIGAND DR5-MEDICINE
JP2016523810A5 (en)
JP2012522513A5 (en)
RU2016111137A (en) DESIGNED CONJUGATES AGAINST DLL3 AND METHODS OF APPLICATION
RU2014124984A (en) COMPOUNDS ANTI-MEDICINAL PRODUCT AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS
RU2016129894A (en) COVALENTLY RELATED HELICAR-ANTIBODY CONJUGATES AGAINST HELICAR AND THEIR APPLICATION
IL276514B1 (en) Glypican 3 antibodies and their conjugates
FI3316909T3 (en) Anti-ntb-a antibodies and related compositions and methods
JP2017535246A5 (en)
JP2023500875A5 (en)
JP2011504460A5 (en)
RU2014138474A (en) NEW MODULATORS AND APPLICATION METHODS
JP2019500020A5 (en)
JP2016531915A5 (en)
JP2009501800A5 (en)